Recent studies have suggested a role for immune dysregulation behind the etiology of frontotemporal lobar degeneration (FTLD). Here, we have investigated the prevalence of immunological diseases in FTLD (N = 196) with and without the C9orf72 repeat expansion, Alzheimer's disease (AD) (N = 193) and not cognitively impaired (NCI) subjects (N = 92). The prevalence was 16.3% in FTLD, 13.5% in AD and 15.2% in NCI. Although differences between the groups did not reach statistical significance, the frequency of immunological diseases was the highest in FTLD without the C9orf72 expansion (22/117, 18.8%) and the lowest in FTLD with the expansion (6/56, 10.7%), suggesting that the C9orf72 expansion possibly influences immunological pathways in FTLD.
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A B S T R A C T
Recent studies have suggested a role for immune dysregulation behind the etiology of frontotemporal lobar degeneration (FTLD). Here, we have investigated the prevalence of immunological diseases in FTLD (N = 196) with and without the C9orf72 repeat expansion, Alzheimer's disease (AD) (N = 193) and not cognitively impaired (NCI) subjects (N = 92). The prevalence was 16.3% in FTLD, 13.5% in AD and 15.2% in NCI. Although differences between the groups did not reach statistical significance, the frequency of immunological diseases was the highest in FTLD without the C9orf72 expansion (22/117, 18.8%) and the lowest in FTLD with the expansion (6/56, 10.7%), suggesting that the C9orf72 expansion possibly influences immunological pathways in FTLD.
Introduction
Frontotemporal lobar degeneration (FTLD) is a group of progressive neurodegenerative syndromes mainly affecting the frontal and temporal lobes of the brain. Clinically FTLD can be divided into two major clinical subgroups: 1) Behavioral variant frontotemporal dementia (bvFTD) characterized by personality changes (Rascovsky et al., 2011) , and 2) primary progressive aphasias (PPA), a group of disorders that manifest as progressive loss of language functions (Gorno-Tempini et al., 2011) . PPAs are further divided into three subgroups based on the clinical profile: non-fluent variant primary progressive aphasia (nfvPPA), semantic variant primary progressive aphasia (svPPA) and logopenic variant primary progressive aphasia (lvPPA), of which the last one is mainly associated with Alzheimer's disease (AD) (GornoTempini et al., 2011) .
FTLD is a neuropathologically and genetically heterogeneous group of diseases. The most common neuropathological subtypes are TDP-43-and Tau-positive FTLD (FTLD-TDP and FTLD-Tau, respectively) (Sieben et al., 2012) . Familial forms of the disease are mainly associated with mutations in C9orf72, MAPT and GRN genes. Hexanucleotide repeat expansion in chromosome 9 open reading frame 72 -gene (C9orf72) is the most common genetic cause for familial FTLD and amyotrophic lateral sclerosis (ALS) (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . The C9orf72 repeat expansion and GRN mutations lead predominantly to TDP-43 neuropathology (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Rohrer et al., 2009) , while mutations in MAPT are associated with tau pathology (Rohrer et al., 2009) . Notably, more than half of the FTLD cases are sporadic without any known genetic alterations (Rohrer et al., 2009 ), but show similar neuropathological features to familial FTLD cases (Cairns et al., 2007) . Despite the recognized pathogenic mutations and different characteristic pathological features, the exact molecular pathogenic mechanisms of FTLD
